Alpine Global Management’s iBio IBIO Stock Holding History

Alpine Global Management’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-450	Closed	-$124K	–	573
2021 Q4	$124K	Buy	+450	New	+$172K	0.02%	606

Other funds holding IBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Alpine Global Management's IBIO Position: Q1 2022 in Review

Alpine Global Management sold out of iBio (IBIO) in Q1 2022, closing a stake of 450 shares — an estimated $124K sold.

Alpine Global Management first reported a position in IBIO in Q4 2021 and held it in 1 quarter. The position peaked at $124K in Q4 2021. 70 funds tracked by Wall St. Rank hold IBIO as of Q1 2022.

Alpine Global Management reported no remaining iBio position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 450 iBio shares in Q1 2022, an estimated $124K.
Alpine Global Management first reported a position in iBio in Q4 2021 and held it in 1 quarter.
Alpine Global Management's iBio position peaked at $124K in Q4 2021.
70 funds tracked by Wall St. Rank held iBio as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.